Ovarian Cancer | Specialty

The OncLive Ovarian Cancer condition center page is a comprehensive resource for clinical news and expert insights on ovarian cancer and evolving treatment approaches, including PARP inhibitors, antibody-drug conjugates, chemotherapy and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in ovarian cancer.

Trabectedin Monotherapy Does Not Improve OS vs Chemotherapy in BRCA-Mutated Recurrent Ovarian Cancer

February 9th 2024

Trabectedin did not offer a survival benefit vs chemotherapy in recurrent ovarian cancer with BRCA-mutated and/or BRCAness phenotype.

HIPEC Plus Surgery Prolongs PFS and OS in Stage III Ovarian Cancer

February 8th 2024

Hyperthermic intraperitoneal chemotherapy plus interval cytoreductive surgery improved progression-free survival in stage III epithelial ovarian cancer.

Dr Smith on the Rationale for Investigating the Predictive Utility of CA-125 KELIM Score in Ovarian Cancer

February 6th 2024

Gabriella Smith, MD, discussed the predictive value of CA-125 KELIM score for survival outcomes with HIPEC during surgery in epithelial ovarian cancer.

FDA Grants Fast Track Designation to BNT325/DB-1305 for Platinum-Resistant Ovarian Cancer

February 5th 2024

FDA grants fast-track status to BNT325/DB-1305 for patients with platinum-resistant ovarian epithelial, fallopian tube, or primary peritoneal cancer.

Dr Crafton on the Use of Mirvetuximab Soravtansine in Ovarian Cancer

February 2nd 2024

Sarah Crafton, MD, discusses the potential future of antibody-drug conjugates in patients with ovarian cancer.

Dr DeBernardo on the Role of PARP Inhibitors in Frontline Ovarian Cancer

January 31st 2024

Robert DeBernardo, MD, discusses the current role of PARP inhibitors in the frontline treatment landscape in ovarian cancer.

Dr Smith on the Predictive Value of CA-125 KELIM Score for Outcomes With HIPEC in Ovarian Cancer

January 26th 2024

Gabriella Smith, MD, discusses the predictive value of CA-125 KELIM score for outcomes with HIPEC during surgery in patients with epithelial ovarian cancer.

CA-125 KELIM Score May Predict Efficacy in Patients With Epithelial Ovarian Cancer Receiving HIPEC During Surgery

January 26th 2024

Gabriella Smith, MD, discusses the potential impact of CA-125 KELIM score for patients with epithelial ovarian cancer undergoing HIPEC during surgery.

Real-World Data Confirm the Incidence of ADC-Related Ocular Toxicities in Ovarian Cancer

January 26th 2024

Susan Marie Lang, MD, discusses real-world data on the incidence of ocular toxicities in patients with ovarian cancer receiving mirvetuximab soravtansine.

Dr Lang on the Association Between Mirvetuximab Soravtansine and Ocular Toxicity in Ovarian Cancer

January 26th 2024

Susan Marie Lang, MD, discusses the incidence of real-world ocular toxicity during treatment with mirvetuximab soravtansine in pretreated ovarian cancer.

Dr Crafton on the Impact of Mirvetuximab Soravtansine on Clinical Practice in Ovarian Cancer

January 25th 2024

Sarah Crafton, MD, discusses the integration of mirvetuximab soravtansine-gynx into clinical practice in the treatment of ovarian cancer.

Dr Miller on Updates With ADCs and Emerging Targets in Ovarian Cancer

January 24th 2024

Eirwen M. Miller, MD, discusses updates on antibody-drug conjugates and emerging targets in ovarian cancer.

Ongoing ADC Development Continues to Gain Traction in Ovarian Cancer

January 24th 2024

Sarah Crafton, MD, discusses the ongoing development of agents targeting key biomarkers in ovarian cancer, such as FRα and HER2; expands on the integration of mirvetuximab soravtansine into clinical practice and its investigation in earlier lines; and emphasizes the importance of continued patient enrollment onto ongoing or planned ADC trials in ovarian cancer.

Dr Miller on the Impact of Mirvetuximab Soravtansine on Clinical Practice in Ovarian Cancer

January 23rd 2024

Eirwen M. Miller, MD, discusses how mirvetuximab soravtansine-gynx in ovarian cancer has bolstered the development of novel ADCs in ovarian cancer.

FDA Grants Fast Track Designation to RC88 in Platinum-Resistant Recurrent Ovarian Cancer

January 12th 2024

The FDA has granted fast-track status to RC88 for use in patients with platinum-resistant recurrent epithelial ovarian cancer.

Dr Crafton on Emerging Therapeutic Targets in Ovarian Cancer

January 10th 2024

Sarah Crafton, MD, discusses novel therapeutic targets under investigation in patients with ovarian cancer.

SH-105 Gets Accepted for FDA Review in Breast and Ovarian Cancer

January 10th 2024

The FDA has announced that it had accepted the new drug application for SH-105 for the treatment of patients with breast and ovarian cancer.

FDA Grants Fast Track Status to Rinatabart Sesutecan for FRα-Expressing Ovarian Cancer

January 8th 2024

The FDA has granted fast track designation to rinatabart sesutecan for the treatment of patients with FRα-expressing high-grade serous or endometrioid platinum-resistant ovarian cancer.

Moore Details Ongoing Research Aiming to Fill Unmet Needs in Ovarian Cancer

December 18th 2023

Kathleen N. Moore, MD, MS, expands on the importance of continuing to investigate PARP inhibitors in ovarian cancer and highlights key updates to have come out of the 2023 ESMO Congress

Dr O'Cearbhaill on Results With Ubamatamab Plus Cemiplimab in Recurrent Ovarian Cancer

December 8th 2023

Roisin E. O'Cearbhaill, MD, discusses key findings from a phase 1/2 dose escalation study of ubamatamab plus cemiplimab in recurrent ovarian cancer.